Starpharma Holdings Limited (SPHRF)

Market Cap	26.05M
Revenue (ttm)	6.51M
Net Income (ttm)	-5.45M
Shares Out	n/a
EPS (ttm)	-0.01
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	3,340
Open	0.0540
Previous Close	0.0558
Day's Range	0.0540 - 0.0540
52-Week Range	0.0662 - 0.1200
Beta	0.77
Analysts	n/a
Price Target	n/a
Earnings Date	Feb 25, 2025

About Starpharma Holdings

Starpharma Holdings Limited, a biopharmaceutical company, engages in the research, development, and commercialization of dendrimer products for pharmaceutical, life science, and other applications worldwide. The company’s products include VivaGel BV, a non-antibiotic vaginal gel for the treatment of bacterial vaginosis (BV) and prevention of recurrent BV; VIRALEZE, an antiviral nasal spray; and VivaGel condom, an antiviral condom coating. It is also involved in the development of dendrimer enhanced product (DEP) delivery platform, consisting of...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1997
• Employees: 40
• Stock Exchange: OTCMKTS
• Ticker Symbol: SPHRF

Financial Performance

In 2024, Starpharma Holdings's revenue was 9.76 million, an increase of 124.64% compared to the previous year's 4.34 million. Losses were -8.17 million, -47.79% less than in 2023.

Financial numbers in AUD